Lurasidone (Latuda) and Ketamine Therapy | Tovani Health
Latuda (Lurasidone) — Atypical antipsychotic
Verdict at Tovani Health
Less sedating antipsychotic; CYP3A4 interactions matter here.
Lurasidone is one of the better-tolerated atypicals for KAP. It is less sedating and has a smaller QT footprint than olanzapine or risperidone. Two specifics matter: lurasidone is a major CYP3A4 substrate, and it must be taken with food (at least 350 calories) for absorption.
If you take Latuda regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Latuda interacts with ketamine
Lurasidone is a D2 and 5-HT2A antagonist with 5-HT1A partial agonism. Absorption is highly food-dependent. Strong CYP3A4 inhibitors (like clarithromycin) are contraindicated and strong inducers (like carbamazepine, rifampin, St. John's Wort) substantially lower lurasidone levels.
What we do at intake
Disclose dose and the meal timing you use. Tell us about any antibiotic or antifungal you start, and about herbal products. If you also take carbamazepine, dose adjustments are needed.
Bottom line
Lurasidone is one of the better-tolerated atypicals for KAP. It is less sedating and has a smaller QT footprint than olanzapine or risperidone. Two specifics matter: lurasidone is a major CYP3A4 substrate, and it must be taken with food (at least 350 calories) for absorption.
Frequently Asked Questions
Does ketamine interact with lurasidone through CYP3A4?
Ketamine is metabolized primarily by CYP3A4 and CYP2B6. The clinical magnitude of any interaction is small at therapeutic KAP doses.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Latuda (Lurasidone) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315
Systematic review of pharmacodynamic interactions between ketamine and psychiatric medications used in depression treatment.
- Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Alnefeesi Y, Chen-Li D, Krane E, et al.. Journal of Psychiatric Research. 2022. PMID: 35688035
Meta-analysis of 2,665 patients across 79 studies — 45% response and 30% remission with ketamine in treatment-resistant depression.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 15, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.